MA32323B1 - Sulfonamides n-hétérocycliques annelés avec un groupe de tête oxadiazolone, procédés pour leur préparation et leur utilisation en tant qu'agents pharmaceutiques - Google Patents

Sulfonamides n-hétérocycliques annelés avec un groupe de tête oxadiazolone, procédés pour leur préparation et leur utilisation en tant qu'agents pharmaceutiques

Info

Publication number
MA32323B1
MA32323B1 MA33378A MA33378A MA32323B1 MA 32323 B1 MA32323 B1 MA 32323B1 MA 33378 A MA33378 A MA 33378A MA 33378 A MA33378 A MA 33378A MA 32323 B1 MA32323 B1 MA 32323B1
Authority
MA
Morocco
Prior art keywords
disorders
preparation
sulfonamides
heterocyclic
oxadiazolone
Prior art date
Application number
MA33378A
Other languages
Arabic (ar)
English (en)
Inventor
Stefanie Keil
Matthias Urmann
Wolfgang Wendler
Maike Glien
Hans Matter
Eugen Falk
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MA32323B1 publication Critical patent/MA32323B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne des sulfonamides n-hétérocycliques annelés avec groupement de tête oxadiazolone, des procédés pour leur préparation et leur utilisation comme médicaments. La présente invention concerne des sulfonamides n-hétérocycliques annelés avec groupement de tête oxadiazolone et leurs sels physiologiquement acceptables et leurs dérivés physiologiquement fonctionnels présentant une activité agoniste ppardelta ou ppardelta et pparalpha. L'invention concerne plus précisément des composés de formule i, dans laquelle les radicaux sont tels que définis, et leurs sels physiologiquement acceptables et des procédés pour leurs préparations. Les composés sont appropriés pour le traitement et/ou la prévention de troubles du métabolisme des acides gras et de troubles dans l'utilisation du glucose ainsi que de troubles dans lesquels l'insulino-résistance est impliquée et de troubles de démyélinisation et autres troubles neurodégénératifs du système nerveux central et périphérique.
MA33378A 2008-06-09 2010-11-30 Sulfonamides n-hétérocycliques annelés avec un groupe de tête oxadiazolone, procédés pour leur préparation et leur utilisation en tant qu'agents pharmaceutiques MA32323B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08290572 2008-06-09
PCT/EP2009/003648 WO2009149820A1 (fr) 2008-06-09 2009-05-22 Sulfonamides n-hétérocycliques annelés avec groupement de tête oxadiazolone, procédés pour leur préparation et leur utilisation comme médicaments

Publications (1)

Publication Number Publication Date
MA32323B1 true MA32323B1 (fr) 2011-05-02

Family

ID=40219356

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33378A MA32323B1 (fr) 2008-06-09 2010-11-30 Sulfonamides n-hétérocycliques annelés avec un groupe de tête oxadiazolone, procédés pour leur préparation et leur utilisation en tant qu'agents pharmaceutiques

Country Status (19)

Country Link
US (2) US8329725B2 (fr)
EP (1) EP2288604B1 (fr)
JP (1) JP2011523664A (fr)
KR (1) KR20110023855A (fr)
CN (1) CN102056921A (fr)
AR (1) AR072013A1 (fr)
AU (1) AU2009256982A1 (fr)
BR (1) BRPI0914978A2 (fr)
CA (1) CA2727373A1 (fr)
CL (1) CL2009001365A1 (fr)
IL (1) IL209805A0 (fr)
MA (1) MA32323B1 (fr)
MX (1) MX2010013264A (fr)
NZ (1) NZ589694A (fr)
RU (1) RU2010154279A (fr)
TW (1) TW201011012A (fr)
UY (1) UY31872A (fr)
WO (1) WO2009149820A1 (fr)
ZA (1) ZA201007679B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2667545A1 (fr) * 2006-10-25 2008-05-02 Neurosearch A/S Composes de type oxadiazole et thiadiazole et leur utilisation comme modulateurs des recepteurs nicotiniques de l'acetylcholine
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
EP2638014B1 (fr) * 2010-11-08 2017-01-04 Lycera Corporation Tétrahydroquinolines et composés bicycliques associés n-sulphonylées pour l'inhibition de l'activité rorgamma et le traitement de maladies
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2013045413A1 (fr) 2011-09-27 2013-04-04 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
CA2871514C (fr) 2012-05-08 2020-08-25 Merck Sharp & Dohme Corp. Tetrahydronaphtyridine et composes bicycliques apparentes pour l'inhibition de l'activite rorgamma et le traitement d'une maladie
EP2847198B1 (fr) 2012-05-08 2016-12-14 Lycera Corporation Tétrahydro[1,8]naphtyridine-sulfonamide et composés apparentés pour utilisation en tant qu'agonistes de ror-gamma et dans le traitement d'une maladie
WO2015095788A1 (fr) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Benzoxazine carbamates de 2-acylamidométhyle et de sulfonylamidométhyle pour l'inhibition de l'activité du rorgamma et le traitement d'une maladie
WO2015095795A1 (fr) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Tétrahydronaphtyridine, benzoxazine, aza-benzoxazine et composés bicycliques apparentés pour l'inhibition de l'activité de rorgamma et le traitement de maladie
US9783511B2 (en) 2013-12-20 2017-10-10 Lycera Corporation Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease
AU2015222917A1 (en) 2014-02-27 2016-09-15 Lycera Corporation Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods
EP3209641A4 (fr) 2014-05-05 2018-06-06 Lycera Corporation Benzènesulfonamido et composés apparentés utilisés en tant qu'agonistes de ror et pour le traitement de maladie
AU2015256190B2 (en) 2014-05-05 2019-08-15 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
US10221142B2 (en) 2015-02-11 2019-03-05 Merck Sharp & Dohme Corp. Substituted pyrazole compounds as RORgammaT inhibitors and uses thereof
AU2016257997A1 (en) 2015-05-05 2017-11-09 Lycera Corporation Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease
CN107980042B (zh) 2015-06-11 2021-10-08 莱斯拉公司 用作RORγ激动剂和用于治疗疾病的芳基二氢-2H-苯并[b][1,4]噁嗪磺酰胺和相关化合物
US10344000B2 (en) 2015-10-27 2019-07-09 Merck Sharp & Dohme Corp. Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof
EP3368535B1 (fr) 2015-10-27 2020-12-02 Merck Sharp & Dohme Corp. Acides benzoïques à substitution hétéroaryle en tant qu'inhibiteurs de rorgammat et leurs utilisations
MX2018005004A (es) 2015-10-27 2018-09-12 Merck Sharp & Dohme Compuestos de indazol substituidos como inhibidores de rorgammat y sus usos.
CN110407721A (zh) * 2019-08-13 2019-11-05 上海毕得医药科技有限公司 一种4-氰基-3-(三氟甲基)苯-1-磺酰氯的合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002040445A1 (fr) * 2000-11-17 2002-05-23 Novo Nordisk A/S Agonistes de glucagon/antagonistes inverses
DE10222034A1 (de) 2002-05-17 2003-11-27 Bayer Ag Tetrahydroisochinolin-Derivate
DE10229777A1 (de) * 2002-07-03 2004-01-29 Bayer Ag Indolin-Phenylsulfonamid-Derivate
US20060258683A1 (en) 2003-04-07 2006-11-16 Liu Kevin Para-sulfonyl substituted phenyl compounds as modulators of ppars
DE10335449A1 (de) 2003-08-02 2005-02-17 Bayer Healthcare Ag Bicyclische Indolinsulfonamid-Derivate
DE10335450A1 (de) 2003-08-02 2005-02-17 Bayer Ag Indolin-Sulfanilsäureamide
EP1586573B1 (fr) 2004-04-01 2007-02-07 Sanofi-Aventis Deutschland GmbH Oxadiazolones, procédé pour leur préparation, usage comme agents pharmaceutiques
AU2005231358A1 (en) 2004-04-01 2005-10-20 Aventis Pharmaceuticals Inc. Use of PPR delta agonists for treating demyelinating diseases
US7601716B2 (en) 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
EP1932843A1 (fr) 2006-12-14 2008-06-18 sanofi-aventis Dérivés de sulfonyl-phenyl-2H(1,2,4) oxadiazole-5-one, procédés de préparation de ceux-ci et leur usage sous forme de médicaments
US8445529B2 (en) * 2008-07-14 2013-05-21 Santen Pharmaceutical Co., Ltd. Indole derivative having, carbamoyl group, ureido group and substituted oxy group
CA2751536A1 (fr) * 2009-02-05 2010-08-12 Kyoto University Derives d'indoline
CN102985422A (zh) * 2010-05-12 2013-03-20 Abbvie公司 激酶的吡咯并吡啶和吡咯并嘧啶抑制剂

Also Published As

Publication number Publication date
ZA201007679B (en) 2011-07-27
EP2288604B1 (fr) 2014-01-08
US20110207738A1 (en) 2011-08-25
NZ589694A (en) 2012-05-25
KR20110023855A (ko) 2011-03-08
US8329725B2 (en) 2012-12-11
IL209805A0 (en) 2011-02-28
TW201011012A (en) 2010-03-16
RU2010154279A (ru) 2012-07-20
CL2009001365A1 (es) 2010-11-05
CN102056921A (zh) 2011-05-11
AR072013A1 (es) 2010-07-28
EP2288604A1 (fr) 2011-03-02
MX2010013264A (es) 2011-02-25
US20120122853A1 (en) 2012-05-17
BRPI0914978A2 (pt) 2015-10-27
CA2727373A1 (fr) 2009-12-17
US8946212B2 (en) 2015-02-03
JP2011523664A (ja) 2011-08-18
UY31872A (es) 2010-01-29
AU2009256982A1 (en) 2009-12-17
WO2009149820A1 (fr) 2009-12-17

Similar Documents

Publication Publication Date Title
MA32323B1 (fr) Sulfonamides n-hétérocycliques annelés avec un groupe de tête oxadiazolone, procédés pour leur préparation et leur utilisation en tant qu'agents pharmaceutiques
MY148982A (en) Phenyl-1,2,4-oxadiazolone derivative with phenyl group, processes for their preparation and their use as pharmaceuticals
MA30981B1 (fr) Derives de sulfonyl-phenyl-2h-(1,2,4)oxadiazol-5-one, procedes de preparation associes et utilisation comme medicaments
TW200602342A (en) Oxadiazolones, processes for their preparation and their use as pharmaceuticals
TN2009000138A1 (fr) Biaryl-ether-urees
MX2010006647A (es) Piridil-n-[1,3,4]-tiadiazol-2-il-bencenosulfonamidas ciclicas, procedimientos para su preparacion y su uso como productos farmaceuticos.
MA29810B1 (fr) 4-oxy-n-[1,3,4]-thiadiazol-2-yl-benzènesulfonamides, procédés pour leur préparation et leur utilisation en tant que produits pharmaceutiques
MA31447B1 (fr) Nouveaux dérivés d'acide dicarboxylique utilisés comme agonistes du récepteur s1p1
MA29805B1 (fr) Derives de phenyl-1.2.4-oxadiazolone, leurs procedes de preparation et leur utilisation comme produits pharmaceutiques
JP6302480B2 (ja) 中枢神経系疾患の治療に有用なトリアゾロ−ピラジン誘導体
TW200621732A (en) Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals
MA37691B1 (fr) 5-amino[1,4]thiazines comme inhibiteurs de bace1
CN112384220A (zh) sGC刺激剂治疗线粒体障碍的用途
HUE032235T2 (en) Azetidinyloxyphenylpyrrolidone compounds
MA29809B1 (fr) N-[1,3,4]-thiadiazol-2-yl-benzenesulfonamides,procedes pour leur preparation et leur utilisation en tant que produits pharmaceutiques
TW200505880A (en) Diarylcycloalkyl derivatives, process for their preparation and their use as pharmaceuticals
TW200500349A (en) Cycloalkylmethoxy-substituted acetic acid derivatives, processes for their preparation and their use as pharmaceuticals
MA29812B1 (fr) N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides cycliques, procedes pour leur preparation et leur utilisation en tant que substances pharmaceutiques
MA27738A1 (fr) Dérivés de cycloalkyle 1,3-substitués contenant des groupes acides, principalement hétérocycliques, procédés de préparation correspondants et utilisation desdits dérivés en tant que médicaments
WO2007039174A3 (fr) [1,3,4]-thiadiazol-2-yl-amides bicycliques de l'acide aryl-sulfonique, leurs procedes de preparation, et leur utilisation en tant que substances pharmaceutiques
MA29806B1 (fr) Derives de 2-aminothiazoles et 2- aminooxazoles,procedes pour leur preparation et leur utilisation en tant que produits pharmaceutiques
US9796722B1 (en) Hepatitis B viral assembly effectors
US20220047587A1 (en) Synergistic compositions comprising r-2-(substituted-sulfonyl)-hexahydro-pyrrolo[1,2-a]pyrazin-6(2h)-ones and s-2-(substituted-sulfonyl)-hexahydro-pyrrolo[1,2-a]pyrazin-6(2h)-ones in a non-racemic ratio
MY140251A (en) Bicyclic aryl-sulfonic acid [1,3,4]-thiadiazol-2-yl-amides, processes for their preparation and their use as pharmaceuticals
TH99135A (th) อนุพันธ์ซัลโฟนิล-เฟนนิล-2h-[1,2,4]ออกซาไดอะโซล-5-โอน ขบวนการเพื่อผลิตสารเหล่านี้และการใช้สารเหล่านี้ในทางเภสัชกรรม